Australia's most trusted
source of pharma news
Posted 11 May 2022
A team of Aussie researchers have discovered a potential combination strategy that could overcome resistance to AbbVie's Venclexta.
In a new study published in the world-leading hematology journal Blood, researchers from UniSA and SA Pathology's Centre for Cancer Biology show a way to suppress a specific protein that promotes resistance to Venclexta when used to treat acute myeloid leukemia (AML) patients.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.